The trial was funded by Sanofi and Regeneron Pharmaceuticals, which are developing sarilumab. Three investigators reported financial ties to Sanofi and/or Regeneron and other manufacturers of drugs for RA, and the rest are employees and/or shareholders of Sanofi or Regeneron or were during the conduct of the study.
News
Investigational interleukin-6 receptor inhibitor for RA shows efficacy, safety
